Propranolol has emerged as a new treatment option for infantile hemangiomas. We describe a 20-month-old boy with a large right parotid hemangioma diagnosed at the age of 37 days. Starting at the age of 2.5 months, he received oral propranolol for 6.5 months. Although the mass regressed, it recurred when propranolol was discontinued. He was successfully retreated at the age of 11 months with pro...

T he main abnormality of the uveal tract in patients with Sturge-Weber syndrome is diffuse choroidal hemangioma (DCH). Diffuse choroidal hemangioma can lead to a total retinal detachment and secondary neovascular glaucoma. Radiotherapy and photodynamic therapy are currently the preferred methods of treatment. Low-dose lens-sparing radiotherapy or proton beam irradiation can induce tumor regress...

Continuous oral propranolol reduces portal venous pressure in patients with cirrhosis.' A controlled trial in such patients who had bled from varices showed a significantly lower incidence of rebleeding in those given propranolol.2 This led to the widespread and enthusiastic use of propranolol to prevent recurrent variceal haemorrhage in patients with cirrhosis. The beneficial effect of propran...

AIM The aim of this study was to investigate the effect of rectal ozone on portal vein oxygenation and the pharmacokinetic changes of propranolol in patients with liver cirrhosis. METHODS Fifteen patients with liver cirrhosis were included They were given a fixed oral dose of propranolol 80mg on the morning of day 1 after overnight fasting. Blood samples were collected at fixed time intervals...

PURPOSE To determine the efficacy and safety of oral propranolol as a first-line treatment for superficially located infantile hemangioma (IH) and propose an assessment tool to measure treatment response. METHODS Patients with superficial IH under 1 year of age were prospectively recruited between May 2012 and December 2013 at the Department of Pediatrics of Chungbuk National University Hospi...

Recent studies in dogs have suggested that the disposition of S- and R-propranolol may depend on the input rate of drug delivered to the liver. Therefore, this study was designed to determine whether differences in the disposition of S- and R-propranolol occur in humans when altering the input rate of propranolol by giving different dosage forms of the drug. Twelve healthy subjects were enrolle...

Propranolol is a nonspecific beta-adrenergic antagonist used for the treatment of cardiac arrhythmias, angina pectoris and hypertension. A significant problem in propranolol therapy is that it undergoes extensive presystemic metabolism after oral administration leading to reduced bioavailability and significantly greater intersubject variability in blood levels after oral than after intravenous...